logo
Plus   Neg
Share
Email

AstraZeneca: Saracatinib Gets FDA's ODD For Idiopathic Pulmonary Fibrosis

British drug maker AstraZeneca Plc (AZN.L,AZN) announced Monday that US Food and Drug Administration has granted Orphan Drug Designation or ODD for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis or IPF.

IPF is a type of lung disease that results in scarring (fibrosis) of the lungs. It is a chronic, progressive, irreversible and usually fatal interstitial lung disease which affects approximately 100,000 people in the US.

IPF causes shortness of breath and progressive damage of the lung, resulting in life-threatening complications such as respiratory failure.

Saracatinib is an inhibitor of src kinase which regulates broad cell functions including cell growth and cell differentiation.

The potential new medicine was discovered by AstraZeneca and has previously been in clinical development in oncology.

Saracatinib has completed Phase I development. Phase II trials for saracatinib in IPF have not yet commenced.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Business software giant Oracle Corp. (ORCL), Wednesday reported a fourth-quarter profit and revenues that trumped Wall Street estimates, reflecting growth in cloud services revenues. Redwood Shores, California-based Oracle reported fourth-quarter profit of $3.74 billion or $1.07 per share, up from... Panera is revamping its menu and has introduced 10 new dinner items to its list as the sandwich chain wants its customers to visit them for even dinner. Panera on Wednesday announced that it is testing an entirely new dinner menu featuring items such as flatbreads, bowls, meatier sandwiches as well... Ann Marie Buerkle, the acting chairwoman of the Consumer Product Safety Commission, has announced her decision to step down as the head of the federal regulatory agency at the end of her term in October. "I have notified the White House that I am withdrawing my nominations to serve as Chairman of...
Follow RTT